SG10201708494QA - Combination therapies for melanoma comprising administering cobimetinib and vemurafinib - Google Patents
Combination therapies for melanoma comprising administering cobimetinib and vemurafinibInfo
- Publication number
- SG10201708494QA SG10201708494QA SG10201708494QA SG10201708494QA SG10201708494QA SG 10201708494Q A SG10201708494Q A SG 10201708494QA SG 10201708494Q A SG10201708494Q A SG 10201708494QA SG 10201708494Q A SG10201708494Q A SG 10201708494QA SG 10201708494Q A SG10201708494Q A SG 10201708494QA
- Authority
- SG
- Singapore
- Prior art keywords
- vemurafinib
- melanoma
- combination therapies
- cobimetinib
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0241—Advertisements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Business, Economics & Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Strategic Management (AREA)
- Accounting & Taxation (AREA)
- Development Economics (AREA)
- Finance (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Entrepreneurship & Innovation (AREA)
- Theoretical Computer Science (AREA)
- General Physics & Mathematics (AREA)
- General Business, Economics & Management (AREA)
- Game Theory and Decision Science (AREA)
- Marketing (AREA)
- Economics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261684673P | 2012-08-17 | 2012-08-17 | |
| US201261705575P | 2012-09-25 | 2012-09-25 | |
| US201261706026P | 2012-09-26 | 2012-09-26 | |
| US201261722725P | 2012-11-05 | 2012-11-05 | |
| US201361780708P | 2013-03-13 | 2013-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201708494QA true SG10201708494QA (en) | 2017-11-29 |
Family
ID=49035547
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201500582UA SG11201500582UA (en) | 2012-08-17 | 2013-08-15 | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
| SG10201913359TA SG10201913359TA (en) | 2012-08-17 | 2013-08-15 | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
| SG10201708494QA SG10201708494QA (en) | 2012-08-17 | 2013-08-15 | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201500582UA SG11201500582UA (en) | 2012-08-17 | 2013-08-15 | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
| SG10201913359TA SG10201913359TA (en) | 2012-08-17 | 2013-08-15 | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US11087354B2 (ko) |
| EP (1) | EP2884979B1 (ko) |
| JP (2) | JP6335169B2 (ko) |
| KR (5) | KR20190057421A (ko) |
| CN (2) | CN104640545A (ko) |
| AU (1) | AU2013304021B2 (ko) |
| BR (1) | BR112015003418A2 (ko) |
| CA (2) | CA2879252C (ko) |
| CL (1) | CL2015000345A1 (ko) |
| CO (1) | CO7180225A2 (ko) |
| DK (1) | DK2884979T3 (ko) |
| EA (1) | EA033573B1 (ko) |
| ES (1) | ES2743427T3 (ko) |
| HK (1) | HK1206605A1 (ko) |
| HR (1) | HRP20191533T1 (ko) |
| HU (1) | HUE044789T2 (ko) |
| IL (1) | IL237065B (ko) |
| LT (1) | LT2884979T (ko) |
| MX (1) | MX367970B (ko) |
| MY (1) | MY180613A (ko) |
| NZ (1) | NZ744862A (ko) |
| PE (1) | PE20151156A1 (ko) |
| PH (1) | PH12015500186A1 (ko) |
| PL (1) | PL2884979T3 (ko) |
| PT (1) | PT2884979T (ko) |
| RS (1) | RS59113B1 (ko) |
| SG (3) | SG11201500582UA (ko) |
| SI (1) | SI2884979T1 (ko) |
| UA (1) | UA114923C2 (ko) |
| WO (1) | WO2014027056A1 (ko) |
| ZA (1) | ZA201500348B (ko) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2884979T (pt) * | 2012-08-17 | 2019-09-04 | Hoffmann La Roche | Terapêuticas combinadas para o melanoma, compreendendo a administração de cobimetinib e vemurafinib |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| WO2015191986A1 (en) * | 2014-06-13 | 2015-12-17 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
| CZ2015250A3 (cs) * | 2015-04-14 | 2016-10-26 | Zentiva, K.S. | Amorfní formy vemurafenibu |
| TWI812581B (zh) * | 2015-05-22 | 2023-08-21 | 美商普雷辛肯公司 | 激酶調節及其適應症 |
| SI3881833T1 (sl) * | 2015-06-30 | 2024-03-29 | Genentech, Inc., | Tablete s takojšnjim sproščanjem, ki vsebujejo zdravilo in postopek za oblikovanje tablet |
| MA43170A (fr) | 2015-11-03 | 2018-09-12 | Univ Texas | Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer |
| EP3377107B1 (en) * | 2015-11-19 | 2020-08-12 | H. Hoffnabb-La Roche Ag | Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors |
| WO2017095826A1 (en) * | 2015-11-30 | 2017-06-08 | The Regents Of The University Of California | Combination therapy for treatment of melanoma |
| BR112019002036A2 (pt) | 2016-08-12 | 2019-05-14 | Genentech Inc | métodos de tratamento de um sujeito com câncer colorretal, kit para tratamento do câncer colorretal em um sujeito humano e combinação de fármacos para a terapia do câncer colorretal |
| JP2019534251A (ja) | 2016-09-29 | 2019-11-28 | ジェネンテック， インコーポレイテッド | Ｍｅｋ阻害剤、ｐｄ−１軸阻害剤、及びタキサンを用いた併用療法 |
| WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| HRP20240069T1 (hr) | 2017-03-02 | 2024-03-29 | Genentech, Inc. | Adjuvantno liječenje her2-pozitivnog raka dojke |
| WO2019139970A1 (en) * | 2018-01-09 | 2019-07-18 | Duke University | Topical administration of mek inhibiting agents for the treatment of skin disorders |
| CN109879855B (zh) * | 2019-03-26 | 2021-01-05 | 中国医学科学院医药生物技术研究所 | 靶向肿瘤细胞表面pd-l1分子的抑制剂及其应用 |
| CN115551509A (zh) * | 2020-05-12 | 2022-12-30 | 诺华股份有限公司 | 包含craf抑制剂的治疗组合 |
| EP4304592A1 (en) | 2021-03-09 | 2024-01-17 | Genentech, Inc. | Belvarafenib for use in treatment of brain cancers |
| WO2022216719A1 (en) | 2021-04-06 | 2022-10-13 | Genentech, Inc. | Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1578346A4 (en) | 2001-12-04 | 2007-11-28 | Onyx Pharma Inc | INHIBITORS OF THE RAF-MEK-ERK PATHWAY TO TREAT CANCER |
| EP2275102B1 (en) | 2002-03-13 | 2015-07-29 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| AU2003286447A1 (en) | 2003-10-16 | 2004-06-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatments for inhibiting development and progression of nevi and melanoma having braf mutations |
| AU2004293018B2 (en) | 2003-11-19 | 2010-02-18 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| PT1696920E (pt) | 2003-12-19 | 2015-01-14 | Plexxikon Inc | Compostos e métodos para o desenvolvimento de moduladores de ret |
| US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| US20060216288A1 (en) | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
| MY153898A (en) | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| US20090202989A1 (en) | 2005-06-28 | 2009-08-13 | Hillan Kenneth J | Egfr and kras mutations |
| US9095581B2 (en) | 2005-07-21 | 2015-08-04 | Ardea Biosciences, Inc. | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof |
| US8101799B2 (en) | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
| WO2007013997A2 (en) | 2005-07-22 | 2007-02-01 | H. Lee Moffitt Cancer Center And Research Institute | Inhibition of the raf/mek/p-erk pathway for treating cancer |
| EP1934174B1 (en) | 2005-10-07 | 2011-04-06 | Exelixis, Inc. | Azetidines as mek inhibitors for the treatment of proliferative diseases |
| AU2007296556B2 (en) * | 2006-09-13 | 2013-09-19 | Takeda Pharmaceutical Company Limited | Use of 2-6- (3-Amino-piperidin-1-yl) -3-methyl-2, 4-dioxo-3, 4-dihydro-2H-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile |
| RU2009114745A (ru) | 2006-09-19 | 2010-10-27 | Новартис АГ (CH) | Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования |
| CA2671982C (en) | 2006-12-14 | 2016-01-26 | Exelixis, Inc. | Methods of using mek inhibitors |
| WO2008112274A2 (en) | 2007-03-13 | 2008-09-18 | Amgen Inc. | K-ras and b-raf mutations and anti-egfr antibody therapy |
| WO2008120004A1 (en) | 2007-04-02 | 2008-10-09 | Astrazeneca Ab | Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer |
| UA99731C2 (ru) | 2007-07-30 | 2012-09-25 | Ардеа Биосайенсис, Инк | Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение |
| AU2009222143A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| ES2392482T3 (es) | 2008-02-29 | 2012-12-11 | Array Biopharma, Inc. | Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF |
| WO2009111279A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Pyrazole [3, 4-b] pyridine raf inhibitors |
| EP2265574A1 (en) | 2008-02-29 | 2010-12-29 | Array Biopharma, Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| MX349923B (es) | 2009-04-03 | 2017-08-21 | Hoffmann La Roche | Composiciones del ácido propano-1-sulfónico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil]-amida y el uso de las mismas. |
| US20120214828A1 (en) | 2009-08-24 | 2012-08-23 | Georgia Hatzivassiliou | Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels |
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| MX345155B (es) * | 2009-10-12 | 2017-01-18 | F Hoffmann-La Roche Ag * | Combinaciones de un inhibidor de pi3k y un inhibidor de mek. |
| WO2011046894A1 (en) | 2009-10-12 | 2011-04-21 | Glaxosmithkline Llc | Combination |
| WO2011104694A2 (en) * | 2010-02-26 | 2011-09-01 | GAMMAGENETICS Sàrl | Detection of braf v600e mutation by allele specific real time quantitative pcr (as-qpcr) using locked nucleic acids primers and beacon probes |
| EP2545187B1 (en) | 2010-03-09 | 2018-09-05 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
| US8426418B2 (en) | 2010-08-27 | 2013-04-23 | CollabRx Inc. | Method to treat melanoma in BRAF inhibitor-resistant subjects |
| AU2011295837B2 (en) * | 2010-09-03 | 2015-06-18 | Astrazeneca Uk Limited | Drug formulations using water soluble antioxidants |
| JP2014505658A (ja) | 2010-11-05 | 2014-03-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド | 癌を治療する方法 |
| KR20130116291A (ko) | 2010-11-19 | 2013-10-23 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | Braf 억제제를 이용한 치료 방법 |
| WO2012068562A2 (en) * | 2010-11-19 | 2012-05-24 | The Regents Of The University Of California | Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas |
| US9295669B2 (en) * | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
| WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
| US20130172375A1 (en) | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
| US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| PT2884979T (pt) * | 2012-08-17 | 2019-09-04 | Hoffmann La Roche | Terapêuticas combinadas para o melanoma, compreendendo a administração de cobimetinib e vemurafinib |
| KR20150118159A (ko) | 2013-02-22 | 2015-10-21 | 에프. 호프만-라 로슈 아게 | 암의 치료 방법 및 약물 내성의 예방 방법 |
-
2013
- 2013-08-15 PT PT13753131T patent/PT2884979T/pt unknown
- 2013-08-15 SI SI201331565T patent/SI2884979T1/sl unknown
- 2013-08-15 KR KR1020197014117A patent/KR20190057421A/ko active Application Filing
- 2013-08-15 KR KR1020177009790A patent/KR20170044759A/ko active Search and Examination
- 2013-08-15 CA CA2879252A patent/CA2879252C/en active Active
- 2013-08-15 PE PE2015000215A patent/PE20151156A1/es not_active Application Discontinuation
- 2013-08-15 CN CN201380042815.XA patent/CN104640545A/zh active Pending
- 2013-08-15 MY MYPI2015700457A patent/MY180613A/en unknown
- 2013-08-15 JP JP2015526987A patent/JP6335169B2/ja active Active
- 2013-08-15 SG SG11201500582UA patent/SG11201500582UA/en unknown
- 2013-08-15 KR KR1020157003834A patent/KR20150038068A/ko active Search and Examination
- 2013-08-15 US US13/967,782 patent/US11087354B2/en active Active
- 2013-08-15 KR KR1020227041809A patent/KR20220165811A/ko not_active IP Right Cessation
- 2013-08-15 BR BR112015003418A patent/BR112015003418A2/pt not_active IP Right Cessation
- 2013-08-15 AU AU2013304021A patent/AU2013304021B2/en active Active
- 2013-08-15 SG SG10201913359TA patent/SG10201913359TA/en unknown
- 2013-08-15 SG SG10201708494QA patent/SG10201708494QA/en unknown
- 2013-08-15 MX MX2015002031A patent/MX367970B/es active IP Right Grant
- 2013-08-15 WO PCT/EP2013/067050 patent/WO2014027056A1/en active Application Filing
- 2013-08-15 EA EA201590262A patent/EA033573B1/ru not_active IP Right Cessation
- 2013-08-15 CN CN201910437096.0A patent/CN110251512A/zh active Pending
- 2013-08-15 ES ES13753131T patent/ES2743427T3/es active Active
- 2013-08-15 EP EP13753131.5A patent/EP2884979B1/en active Active
- 2013-08-15 KR KR1020217027317A patent/KR20210108502A/ko not_active IP Right Cessation
- 2013-08-15 NZ NZ744862A patent/NZ744862A/en unknown
- 2013-08-15 CA CA2928396A patent/CA2928396A1/en not_active Abandoned
- 2013-08-15 RS RS20191053A patent/RS59113B1/sr unknown
- 2013-08-15 LT LTEP13753131.5T patent/LT2884979T/lt unknown
- 2013-08-15 DK DK13753131.5T patent/DK2884979T3/da active
- 2013-08-15 PL PL13753131T patent/PL2884979T3/pl unknown
- 2013-08-15 HU HUE13753131 patent/HUE044789T2/hu unknown
- 2013-08-15 UA UAA201501710A patent/UA114923C2/uk unknown
-
2015
- 2015-01-16 ZA ZA2015/00348A patent/ZA201500348B/en unknown
- 2015-01-27 CO CO15016085A patent/CO7180225A2/es unknown
- 2015-01-28 PH PH12015500186A patent/PH12015500186A1/en unknown
- 2015-02-02 IL IL237065A patent/IL237065B/en active IP Right Grant
- 2015-02-13 CL CL2015000345A patent/CL2015000345A1/es unknown
- 2015-07-27 HK HK15107148.9A patent/HK1206605A1/xx unknown
-
2017
- 2017-04-06 JP JP2017075880A patent/JP2017160214A/ja active Pending
-
2019
- 2019-08-27 HR HRP20191533 patent/HRP20191533T1/hr unknown
-
2021
- 2021-08-09 US US17/444,691 patent/US11783366B2/en active Active
-
2023
- 2023-08-17 US US18/451,452 patent/US20240046303A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1206605A1 (en) | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib cobimetinib | |
| HK1202545A1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| HK1211475A1 (en) | Combination therapy | |
| HK1205298A1 (en) | Hardware and software association and authentication | |
| HK1203493A1 (en) | Substituted azabicycles and use thereof | |
| EP2884984A4 (en) | THERAPEUTIC COMPOSITIONS AND METHOD | |
| EP2867209A4 (en) | COMPOUNDS AND THEIR THERAPEUTIC USES | |
| EP2806918A4 (en) | PROCESSES AND DEVICES FOR SPRAYING WITH AUTOMATIC RINSING | |
| PT2914254T (pt) | Terapias de combinação para tratar cancros quimiorresistentes | |
| EP2875014A4 (en) | ANTI-MUCUS MEDICAMENTS AND USES THEREOF | |
| GB201216649D0 (en) | Agents and methods | |
| GB201217439D0 (en) | Combination therapy | |
| HK1203198A1 (en) | Substituted phenylimidazopyrazoles and use thereof | |
| HK1210426A1 (en) | Combination therapy | |
| EP2895186A4 (en) | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | |
| EP2817004A4 (en) | BOUVARDIN DERIVATIVES AND THEIR THERAPEUTIC USES | |
| HK1207154A1 (en) | C1q-adiponectin complex and use thereof c1q- | |
| GB201222541D0 (en) | Kiddibidet and pottibidet | |
| GB201214493D0 (en) | Therapies | |
| IL218974A0 (en) | Conaction bitwen coutch and playels | |
| GB201202945D0 (en) | Novel cancer therapies and methods | |
| GB201202021D0 (en) | Co-sleeper and breastfeeder | |
| EP2922862A4 (en) | COMPLEX FORMING MODULATING ACTIVE SUBSTANCES AND USES THEREOF | |
| GB201418806D0 (en) | Generating and partitioning polynomials | |
| GB201211543D0 (en) | Combination therapy |